XBiotech Inc. (XBIT) Shares Down 2.4%
XBiotech Inc. (NASDAQ:XBIT) shares traded down 2.4% on Monday . The company traded as low as $13.06 and last traded at $13.27, with a volume of 68,585 shares changing hands. The stock had previously closed at $13.59.
A number of research analysts recently weighed in on the stock. Noble Financial reiterated a “buy” rating and issued a $30.00 price objective (up from $24.00) on shares of XBiotech in a research note on Tuesday, June 28th. Zacks Investment Research upgraded shares of XBiotech from a “hold” rating to a “buy” rating and set a $15.00 price objective for the company in a research note on Tuesday, May 24th.
The firm’s market capitalization is $431.80 million. The firm’s 50-day moving average price is $14.26 and its 200-day moving average price is $13.86.
Several large investors have recently bought and sold shares of the stock. BlackRock Advisors LLC boosted its stake in XBiotech by 445.4% in the second quarter. BlackRock Advisors LLC now owns 5,929 shares of the biopharmaceutical company’s stock worth $124,000 after buying an additional 4,842 shares during the last quarter. Vanguard Group Inc. boosted its stake in XBiotech by 26.6% in the second quarter. Vanguard Group Inc. now owns 502,618 shares of the biopharmaceutical company’s stock worth $10,515,000 after buying an additional 105,511 shares during the last quarter. UBS Asset Management Americas Inc. purchased a new stake in XBiotech during the second quarter worth approximately $285,000. Nationwide Fund Advisors boosted its stake in XBiotech by 335.3% in the second quarter. Nationwide Fund Advisors now owns 11,292 shares of the biopharmaceutical company’s stock worth $236,000 after buying an additional 8,698 shares during the last quarter. Finally, DekaBank Deutsche Girozentrale boosted its stake in XBiotech by 28.6% in the second quarter. DekaBank Deutsche Girozentrale now owns 18,000 shares of the biopharmaceutical company’s stock worth $376,000 after buying an additional 4,000 shares during the last quarter. Hedge funds and other institutional investors own 8.61% of the company’s stock.
XBiotech Company Profile
XBiotech Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing True Human monoclonal antibodies for treating a range of diseases. The Company focuses on bringing its lead product candidate, Xilonix (MABp1), to market. The Company has also developed a True Human monoclonal antibody discovery platform and manufacturing system.
Receive News & Ratings for XBiotech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XBiotech Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.